View Older Stories View More Recent Stories

Nov 30, 2020 07:03AM Anavex Life Sciences (AVXL) Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 for Treatment of Rett Syndrome and other Neurodevelopmental Disorders
Nov 30, 2020 07:00AM Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmenta
Nov 25, 2020 07:00AM Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 6, 2020 10:46AM Anavex Life Sciences (AVXL) Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD
Nov 6, 2020 10:45AM Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference
Oct 15, 2020 07:02AM Anavex Life Sciences (AVXL) Reports Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX2-73 in Parkinson's Disease Dementia
Oct 15, 2020 07:00AM Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia
Sep 10, 2020 07:04AM Anavex Life Sciences (AVXL) Reports Completion of ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 10, 2020 07:00AM Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 8, 2020 07:00AM Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences
Aug 19, 2020 07:00AM Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s
Aug 6, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
Aug 5, 2020 05:36PM Anavex Life Sciences (AVXL) Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
Aug 5, 2020 04:05PM Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
Aug 4, 2020 07:00AM Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020
Jul 6, 2020 07:04AM Anavex Life Sciences (AVXL) Reports First Participant Enrolled in Phase 1 Study of ANAVEX3-71 (AF710B)
Jul 6, 2020 07:00AM Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
Jul 1, 2020 07:01AM Anavex Life Sciences (AVXL) Reports First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome
Jul 1, 2020 07:00AM Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome
Jun 16, 2020 07:03AM Anavex Life Sciences (AVXL) Reports Patient Enrollment Exceeded Target for ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Jun 16, 2020 07:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
Jun 4, 2020 07:08AM Anavex Life Sciences (AVXL) Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX2-73 into Multinational Clinical Trial for AD
Jun 4, 2020 07:00AM Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
May 21, 2020 07:07AM Anavex Life Sciences (AVXL) Begins First-in-Human Phase 1 Study of ANAVEX3-71 (AF710B)
May 21, 2020 07:00AM Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
May 7, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates
May 5, 2020 07:00AM Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020
Apr 23, 2020 07:11AM Anavex Life Sciences (AVXL) Announces Publication of Clinical Data for ANAVEX2-73 in Alzheimer's Disease
Apr 23, 2020 07:00AM Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease
Mar 31, 2020 07:05AM Anavex Life Sciences (AVXL) Provides Update on Clinical Program Development as Response to COVID-19
Mar 31, 2020 07:00AM Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
Mar 23, 2020 08:00AM Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders
Feb 24, 2020 07:07AM Anavex Life Sciences (AVXL) Announces Publication of Foundational Data for ANAVEX2-73 in MS
Feb 24, 2020 07:00AM Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS)
Feb 6, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates
Feb 6, 2020 07:00AM Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates
Feb 4, 2020 07:00AM Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference
Feb 4, 2020 07:00AM Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference
Feb 3, 2020 07:05AM Anavex Life Sciences (AVXL) Announces FDA Fast Track Designation Granted for ANAVEX2-73 Clinical Development Program for Treatment of Rett Syndrome
Feb 3, 2020 07:00AM Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome
Feb 3, 2020 07:00AM Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome
Jan 30, 2020 07:00AM Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020
Jan 27, 2020 07:07AM Anavex Life Sciences (AVXL) Reports Complete Target Enrollment for ANAVEX2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial
Jan 27, 2020 07:00AM Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial
Jan 8, 2020 07:08AM Anavex Life Sciences (AVXL) Issued New U.S. Patent for ANAVEX 2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and MS
Jan 8, 2020 07:00AM Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis
Dec 16, 2019 07:00AM Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates
Dec 10, 2019 07:00AM Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019
Dec 4, 2019 07:05AM Anavex Life Sciences (AVXL) Highlights ANAVEX2-73 (blarcamesine) Data at CTAD 2019 Meetings
Dec 4, 2019 07:00AM Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference
View More Recent Stories View Older Stories